Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462680 · ClinicalTrials.gov registry record · NA
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
A NA study of Parkinson's Disease, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT03462680: Completed NA study of Parkinson's Disease, sponsored by VA Office of Research and Development.
NCT03462680 is a NA study of Parkinson's Disease that has completed, run by VA Office of Research and Development. The registered enrollment target is 47 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03462680, a NA study of Parkinson's Disease, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD. The investigators also found that individuals with PD have a chronic niacin deficiency . The purposes of this study are to (1) examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 6 months of vitamin B3 supplements may reduce the inflammation and/or improve symptoms.
Primary Outcome
This is the Unified Parkinson's disease rating scale assessment. The investigators assess I, II, III and V components of the UPDRS. UPDRS 3 is motor skills. Higher scores mean worse outcome. A 0 is minimum and 120 is the maximum.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT niacin
Study Locations (1)
Georgia
- Charlie Norwood VA Medical Center, Augusta, GA - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2020-04-23 |
| Phase | NA |
What the finished NCT03462680 record still lists
NCT03462680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT03462680 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03462680 about?
NCT03462680 is a clinical study titled "GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures". Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD. The investigators also found that individuals with PD have a chronic niacin deficiency . The purposes o...
What is the current status of trial NCT03462680?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2016-09-28. Estimated completion is 2020-04-23.
What conditions does trial NCT03462680 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT03462680?
The interventions under investigation include: placebo (OTHER), niacin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03462680?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03462680 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03462680's enrollment target sits among peer trials
47 89th of 158 higher than 70 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease
RECRUITING · NA
-
Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease
RECRUITING · NA
-
Deep Brain Stimulation Therapy in Movement Disorders
RECRUITING · NA
-
Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI